news
Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
List view / Grid view
ObsEva
news
ObsEva Phase II trial shows meaningful increase in pregnancy and live birth rates
28 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The results of ObsEva’s trial of OBE001 (nolasiban) showed improvement in clinical pregnancy and live birth rates in women undergoing embryo transfer...
article
Time to address the unmet need in women’s reproductive health
20 September 2016 | By Ernest Loumaye, MD, PhD, Co-Founder & Chief Executive Officer, ObsEva
Ernest Loumaye, PhD, Co-Founder & Chief Executive Officer of ObsEva discusses the unmet need of women's reproductive health and what's in the pipeline for treatment...
news
ObsEva initiates Phase 1 clinical program of OBE022 for the treatment of preterm labor
28 July 2016 | By ObsEva
ObsEva initiates Phase 1 clinical program of OBE022, a first-in-class orally active Prostaglandin F2alpha antagonist, for the treatment of preterm labor...
